Chimeric (ASX:CHM) share price edges lower despite positive update

The Chimeric Therapeutics Ltd (ASX: CHM) share price is sliding in afternoon trade despite a positive update. Here’s what the company said.

| More on:
asx share price fall represented by lady in striped tshirt making sad face against orange background

Image source: Getty Images

The Chimeric Therapeutics Ltd (ASX: CHM) share price is sliding in mid-afternoon trade. This comes despite the company announcing the successful completion of its CLTX CAR T phase 1 trial.

Established in 2020, Chimeric is developing a breakthrough cancer cell therapy drug for solid tumours. The company uses chlorotoxin, which comes from scorpion venom, to bind and direct T cells to target glioblastoma (GBM). Initial scientific research conducted at the City of Hope Cancer Centre in Los Angeles found promising anti-tumour activity from CAR T therapy.

At the time of writing, the biotechnology company’s shares are going for 29 cents apiece, down 1.6%.

What did Chimeric announce?

Investors appear unfazed by the company’s latest update, sending Chimeric shares lower.

According to its release, Chimeric advised it has passed the first checkpoint in the City of Hope’s phase 1 CLTX CAR T cell clinical trial. All patients in the first group that received the Chlorotoxin CAR T dose have exceeded the 28-day follow-up period without experiencing dose-limiting toxicities.

The dose-escalation study is seeking to assess Chlorotoxin CAR T’s safety and maximum tolerance in participants suffering from recurrent or progressive GBM.

While the first cohort received the minimum dosage limit, Chimeric will now move onto the second dosing level. Patients in this group will be administered via two methods – intratumoral (ICT) and intracranial intraventricular (ICV) at a total dose of 88 x 106 CAR T cells.

Chimeric hopes to recruit between 18 to 36 people with MMP2+ recurrent or progressive GBM across 4 different dose levels. Once the appropriate dosing amount is established, the company will then move to phase 2 trials.

Chimeric chief operating officer, Jennifer Chow commented on the achievement:

We are very pleased to have reached this significant milestone with our CLTX CAR T cell therapy as it enables us to advance the development of this important therapy for patients with progressive or recurrent Glioblastoma.

We look forward to further progressing the development of CLTX CAR T and to providing updates as we seek to bring the promise of cell therapy to life for more patients with cancer.

About the Chimeric share price

Since coming online to the ASX at the start of this year, the Chimeric share price has remained relatively flat. The company’s shares reached an all-time high of 44 cents in late January, before treading lower.

Based on the current share price, Chimeric has a market capitalisation of roughly $57 million.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Two children put their hands in the air on a rollercoaster ride.
Share Market News

Why have ASX 200 shares popped then dropped on Monday?

What’s happening to the ASX 200 for it to be volatile?

Read more »

Arrows pointing upwards with a man pointing his finger at one.
Share Market News

Here are the 3 most traded ASX 200 shares on Monday

We take a look at the most traded ASX 200 shares by volume today.

Read more »

A man with a scrappy beard and wearing dark sunglasses and a beanie head covering raises a fist in happy celebration as he sits at is computer in a home environment.
Share Market News

Archer Materials share price leaps 7% on patent news

It's good news today for the ASX materials tech company.

Read more »

A young man has a look of alarm on his face as he turns to see the close up face of a brown grizzly bear that is draped over him as part of a large life-size bear skin rug he is wearing over his shoulders.

Ethereum price rout knocks founder from billionaire’s list. Does he still ‘welcome a bear market’?

The crypto selloff should offer more clarity on which projects are 'long-term sustainable'.

Read more »

A group of market analysts sit and stand around their computers in an open-plan office environment. The central figures are deep in thought about Megaport's recent earnings release
Share Market News

ASX 200 midday update: Elders and Codan rocket, Incitec Pivot disappoints

The ASX 200 index has started the week on a mildly positive note...

Read more »

stylised silhouette of a bear on financial graph background
Share Market News

These are the 10 most shorted ASX shares

Short sellers are currently targeting these ASX shares...

Read more »

Smiling man with phone in wheelchair watching stocks and trends on computer
Share Market News

5 things to watch on the ASX 200 on Monday

Here's what to expect on the ASX 200 on Monday...

Read more »

A group of people in suits watch as a man puts his hand up to take the opportunity.
Blue Chip Shares

2 ASX blue-chip shares this top fund manager thinks are good value

Wilson Asset Management offers its thoughts on a couple of blue-chip shares.

Read more »